MIR502

Summary

MIR502 (microRNA 502, HGNC:32136) is a microRNA gene on chromosome Xp11.23.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 574504 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32136
Approved symbol	MIR502
Name	microRNA 502
Location	Xp11.23
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-502
Ensembl gene	ENSG00000272080
Ensembl biotype	miRNA
OMIM	300893
Entrez	574504
RNAcentral	URS000075A647 — miRNA, 86 nt, 3 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000606349

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000606349 — 1 exons

Exon	Start	End
ENSE00003701092	50014598	50014683

Expression profiles

Bgee: expression breadth broad, 11 present calls, max score 84.33.

Top tissues by expression

11 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	84.33	gold quality
colon	UBERON:0001155	82.62	gold quality
intestine	UBERON:0000160	82.18	gold quality
kidney	UBERON:0002113	75.03	gold quality
liver	UBERON:0002107	68.74	gold quality
esophagus mucosa	UBERON:0002469	66.64	gold quality
tibial artery	UBERON:0007610	66.34	gold quality
stomach	UBERON:0000945	65.72	gold quality
skin of abdomen	UBERON:0001416	63.08	gold quality
skin of leg	UBERON:0001511	63.07	gold quality
spleen	UBERON:0002106	60.92	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.49

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 33)

• The miR-502-binding site single-nucleotide polymorphism in the 3’-UTR of SET8 modulates SET8 expression and contributes to the early development of breast cancer. (PMID:19789321)
• SET8 modifies hepatocellular carcinoma outcome by altering its expression, which depends, at least in part, on its binding affinity with miR-502. (PMID:22095217)
• miR-502 may function as a potential tumor suppressor and therefore be a novel candidate for developing miR-502-based therapeutic strategies. (PMID:22580605)
• SET8 CC genotype was associated with a decreased risk of EOC in this case-control study. The analysis of genetic polymorphisms in miRNA binding sites may help identify subgroups of populations that are at high risk for EOC (PMID:22867998)
• Genetic variation in a microRNA-502 minding site in SET8 gene confers clinical outcome of non-small cell lung cancer in a Chinese population. (PMID:24146953)
• significant association between the polymorphism (rs16917496) of the miR-502-binding site in the 3’-UTR of SET8 and TP53 codon 72 polymorphism and the risk of developing NSCLC. (PMID:24374662)
• miR-502-5p may act as a tumor-suppressor gene by targeting oncogenic TRAF2 in breast cancer and, therefore, may be a potential diagnostic and anticancer therapeutic marker for breast cancer. (PMID:24677135)
• evaluate the impact of rs16917496 polymorphism within the miR-502 miRNA seed region at the 3’UTR of SEDT8 on childhood acute lymphoblastic leukemia (PMID:25048968)
• High MIR502 expression is associated with atypical coronary artery disease. (PMID:25198728)
• The SNP in the miR502 binding site of the SET8 3’-untranslated region seems to influence survival of non-Hodgkin’s lymphoma. (PMID:25343552)
• findings suggest that miR-502 functions as a tumor suppressor in HCC via inhibition of PI3KCG, supporting its utility as a promising therapeutic gene target for this tumor type (PMID:26163264)
• miR-502/SET8 regulatory circuit emerges as a key regulator of the pathobiology of breast cancer and a focal point for possible therapeutic intervention. (PMID:27080302)
• MiR-502 medaited histone methyltransferase SET8 expression is associated with outcome of esophageal squamous cell carcinoma. (PMID:27605386)
• rs56288038 (C/G) in IRF-1 3’UTR acted as a promotion factor in gastric cancer development through enhancing the regulatory role of miR-502-5p in IRF-1 expression. (PMID:27866197)
• Genetic changes in miR-146a and the miR-502 binding site of the SET8 can be effective on the increased risk of breast cancer. (PMID:29128203)
• data suggest that persistent elevated levels of miR-502-5p participate in the development of aneurysmal subarachnoid hemorrhage (aSAH) and may help physicians to adjust therapy for aSAH (PMID:29689401)
• miR-502 enhanced the phosphorylation levels of AKT pathways, which may be the mechanism of the overgrowth for esophageal cancer cells. (PMID:29709473)
• Results found that miR-502 was downregulated in gastric cancer (GC) tissues, inhibited cell proliferation and invasion, and reversed the tumor-promoting effects of circDLST in GC cells. (PMID:30953514)
• CCND1, DNMT3B and NOP14 were identified as direct targets of miR-502-5p. (PMID:31971654)
• CDKN1B Mediates Apoptosis of Neuronal Cells and Inflammation Induced by Oxyhemoglobin via miR-502-5p After Subarachnoid Hemorrhage. (PMID:32152938)
• Circ_0032627 accelerates proliferation of gastric cancer cells through regulating miR-502-5p expression. (PMID:32633357)
• Circular RNA circ_001842 plays an oncogenic role in renal cell carcinoma by disrupting microRNA-502-5p-mediated inhibition of SLC39A14. (PMID:32729666)
• Circ_0020397 regulates the viability of vascular smooth muscle cells by up-regulating GREM1 expression via miR-502-5p in intracranial aneurysm. (PMID:33242525)
• Hsa_circ_0032131 knockdown inhibits osteoarthritis progression via the miR-502-5p/PRDX3 axis. (PMID:34032607)
• Study on Omentin-1 and miR-502-3p in osteoporotic fracture. (PMID:34059576)
• LncRNA LINC00473 is involved in the progression of invasive pituitary adenoma by upregulating KMT5A via ceRNA-mediated miR-502-3p evasion. (PMID:34091587)
• MicroRNA miR-502-5p inhibits ovarian cancer genesis by downregulation of GINS complex subunit 2. (PMID:34288816)
• MicroRNA5023p promotes Mycobacterium tuberculosis survival in macrophages by modulating the inflammatory response by targeting ROCK1. (PMID:34476503)
• CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502-5p/KRAS and IGF2BP2/Myc axes. (PMID:34696797)
• Homo sapiens circular RNA 0003602 (Hsa_circ_0003602) accelerates the tumorigenicity of acute myeloid leukemia by modulating miR-502-5p/IGF1R axis. (PMID:34988853)
• Circular RNA SOX5 promotes the proliferation and inhibits the apoptosis of the hepatocellular carcinoma cells by targeting miR-502-5p/synoviolin 1 axis. (PMID:35048790)
• Hsa_circ_0079557 Promotes the Proliferation of Colorectal Cancer Cells Through the hsa_circ_0079557/miR-502-5p/CCND1 Axis. (PMID:37889059)
• Long noncoding RNA SNHG3 interacts with microRNA-502-3p to mediate ITGA6 expression in liver hepatocellular carcinoma. (PMID:38680094)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir500	ENSMUSG00000070108
rattus_norvegicus	Mir500	ENSRNOG00000036262

Paralogs (3): MIR500A (ENSG00000207785), MIR501 (ENSG00000211538), MIR500B (ENSG00000239057)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.